Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Anthony M. Hunter, Mrinal M. Patnaik, Raphael Itzykson, Ruben Mesa, Chatchada Karanes, Yanxia Li, R. Angelo de Claro, Kelly J. Norsworthy, Marc Theoret, Elizabeth Pulte, Eric Padron

Blood (2024) 144 (19): 1987–1992.

https://doi.org/10.1182/blood.2024025648

Published: 2024

Journal Articles

Minimal Residual Disease (MRD) Data in Hematologic Malignancy Drug Applications and Prescribing Information: FDA Analysis

Maryam Sarraf Yazdy, Andrea C. Baines, Theresa Carioti, Rachel Ershler, Emily Y. Jen, Bindu Kanapuru, Yvette L. Kasamon, Ashley Lane, Nicholas Richardson, Marc Theoret, Nicole J. Gormley

Blood (2021) 138 (Supplement 1): 4928.

https://doi.org/10.1182/blood-2021-150446

Published: 2021

Journal Articles

Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses

Nina Kim, Jonathon Vallejo, Jonathan Herz, Thomas Gwise, R. Angelo de Claro, Marc Theoret, Richard Pazdur, Kelly J. Norsworthy

Blood (2021) 138 (Supplement 1): 2604.

https://doi.org/10.1182/blood-2021-147558

Published: 2021

Journal Articles

FDA Analysis of Screen Failures By Race in Clinical Trials of Acute Myeloid Leukemia

Dianne Pulte, MD, Guo Wei, Kelly J. Norsworthy, MD, Yutao Gong, PhD, Nicole J. Gormley, MD, Bindu Kanapuru, MD, Richard Pazdur, MD, Julie Schneider, Marc Theoret, MD, Angelo De Claro, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136363

Published: 2020

Journal Articles

FDA Analysis: Impact of Body Mass Index (BMI) on Outcomes in Relapsed-Refractory Multiple Myeloma

Rachel Ershler, MD, Bindu Kanapuru, MD, Yutao Gong, PhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Ola Landgren, MD PhD, Marc Theoret, MD, Nicole J Gormley, MD, Ann T. Farrell, MD, Richard Pazdur, MD

Blood (2019) 134 (Supplement_1): 5505.

https://doi.org/10.1182/blood-2019-130551

Published: 2019

NARROW

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Minimal Residual Disease (MRD) Data in Hematologic Malignancy Drug Applications and Prescribing Information: FDA Analysis

Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses

FDA Analysis of Screen Failures By Race in Clinical Trials of Acute Myeloid Leukemia

FDA Analysis: Impact of Body Mass Index (BMI) on Outcomes in Relapsed-Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Minimal Residual Disease (MRD) Data in Hematologic Malignancy Drug Applications and Prescribing Information: FDA Analysis

Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses

FDA Analysis of Screen Failures By Race in Clinical Trials of Acute Myeloid Leukemia

FDA Analysis: Impact of Body Mass Index (BMI) on Outcomes in Relapsed-Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only